Close
Close
People News

Leading Commercial and Transational Healthcare Exectutive Shawn Cline Tomasello Joins Mesoblast Board

4.0
4.0 from 1 vote
Wednesday, July 11, 2018

New York, USA; and Melbourne, Australia - Mesoblast Limited (ASX: MSB; Nasdaq: MESO) announced that Shawn Cline Tomasello has joined its Board of Directors. With more than 30 years’ experience in the pharmaceutical and biotech industries, Ms Tomasello brings substantial commercial and transactional experience to the Mesoblast board.

Since 2015, Ms Tomasello has been Chief Commercial Officer at leading immuno-oncology cell therapy company Kite Pharma, where she played a pivotal role in the company’s acquisition in 2017 by Gilead Sciences for $11.9 billion. Prior to this she served as Chief Commercial Officer at Pharmacyclics, Inc., which was acquired in 2015 by AbbVie, Inc. for $21 billion. Ms Tomasello previously was President of the Americas, Hematology and Oncology at Celgene Corporation where she managed over $4 billion in product revenues, and was instrumental in various global expansion and acquisition strategies. She has also held senior positions at Genentech, Pfizer Laboratories, Miles Pharmaceuticals and Procter & Gamble. Ms Tomasello currently serves on the Board of Directors of Centrexion Therapeutics, Oxford BioTherapeutics and Diplomat Rx.

Commenting on her appointment, Ms Tomasello said, “I have been extremely impressed by Mesoblast’s technology and the rigor with which the company has moved its programs towards commercialization. Mesoblast’s cellular medicines have the potential to make a substantial impact on the treatment of life-threatening conditions in a way not possible with traditional approaches. I look forward to making an important contribution to Mesoblast’s commercial and strategic objectives.”

Mesoblast Chief Executive Dr Silviu Itescu stated: “Shawn’s substantial commercial experience will be invaluable to the Mesoblast product launch team as we transition to a commercial-stage company. As important, Shawn’s unparalleled transactional experience will greatly strengthen our ability to execute on our strategic objectives.”

Ignite Partners advised Mesoblast on the appointment of Ms Tomasello.

About Mesoblast
Mesoblast Limited (ASX: MSB; Nasdaq: MESO) is a world leader in developing allogeneic (off-the-shelf) cellular medicines. The Company has leveraged its proprietary technology platform to establish a broad portfolio of late-stage product candidates with three product candidates in Phase 3 trials – acute graft versus host disease, chronic heart failure and chronic low back pain due to degenerative disc disease. Through a proprietary process, Mesoblast selects rare mesenchymal lineage precursor and stem cells from the bone marrow of healthy adults and creates master cell banks, which can be industrially expanded to produce thousands of doses from each donor that meet stringent release criteria, have lot to lot consistency, and can be used off-the-shelf without the need for tissue matching. Mesoblast has facilities in Melbourne, New York, Singapore and Texas and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO). www.mesoblast.com

Contacts:
Julie Meldrum
Corporate Communications
T: +61 3 9639 6036
E: julie.meldrum@mesoblast.com

Chond Greenway
Investor Relations
T: +1 212 880 2060
E: schond.greenway@mesoblast.com

Source: Mesoblast
4.0
4.0 from 1 vote
Free Newsletter
Videos
by Abidemi Uruejoma
5 views
by Abidemi Uruejoma
19 views
by Abidemi Uruejoma
20 views
by Abidemi Uruejoma
48 views